| 1 |
34792626 | Lack of miRNA-17 family mediates high glucose-induced PAR-1 upregulation in glomerular mesangial cells. | 2022 Jan |
1 |
| 2 |
35006035 | Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. | 2022 Jan-Dec |
1 |
| 3 |
35054966 | PAR4-Mediated PI3K/Akt and RhoA/ROCK Signaling Pathways Are Essential for Thrombin-Induced Morphological Changes in MEG-01 Cells. | 2022 Jan 11 |
1 |
| 4 |
32762584 | Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants. | 2021 Aug 18 |
1 |
| 5 |
33255066 | Vorapaxar-modified polysulfone membrane with high hemocompatibility inhibits thrombosis. | 2021 Jan |
1 |
| 6 |
33776786 | PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. | 2021 |
1 |
| 7 |
34137222 | Ca mobilization and signaling pathways induced by rRgpB in human gingival fibroblast. | 2021 Apr 25 |
1 |
| 8 |
34653426 | Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function. | 2021 Dec 1 |
2 |
| 9 |
34791291 | PAR-1 Antagonism to Promote Gut Mucosa Healing in Crohn's Disease Patients: A New Avenue for CVT120165. | 2021 Nov 15 |
1 |
| 10 |
34944024 | Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation. | 2021 Dec 13 |
4 |
| 11 |
34966687 | Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms. | 2021 |
2 |
| 12 |
31444884 | Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. | 2020 Jan |
1 |
| 13 |
31877279 | Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells. | 2020 Feb 15 |
1 |
| 14 |
32308016 | Vorapaxar in the treatment of cardiovascular diseases. | 2020 Sep |
1 |
| 15 |
32639031 | Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19? | 2020 Nov |
1 |
| 16 |
33078834 | The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. | 2020 Nov 13 |
1 |
| 17 |
33138025 | Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains. | 2020 Oct 29 |
3 |
| 18 |
30324870 | Oral antiplatelet agents in cardiovascular disease. | 2019 Jul |
1 |
| 19 |
31291665 | Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo. | 2019 Sep |
1 |
| 20 |
28403576 | No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers. | 2018 Feb |
1 |
| 21 |
28565918 | Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. | 2018 Jan |
1 |
| 22 |
29731231 | Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist. | 2018 Jun 5 |
2 |
| 23 |
29763961 | The Novel Protease-Activated Receptor 1 Antagonist Vorapaxar as a Treatment for Thrombosis in Afibrinogenemia. | 2018 Jun |
1 |
| 24 |
29864779 | Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia. | 2018 Jul |
1 |
| 25 |
30102523 | Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule. | 2018 Oct 2 |
4 |
| 26 |
30257802 | Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. | 2018 Oct |
1 |
| 27 |
30526198 | Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. | 2018 Dec 18 |
1 |
| 28 |
30568593 | TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1. | 2018 |
1 |
| 29 |
27075924 | Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial. | 2017 Mar |
1 |
| 30 |
27489245 | Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us. | 2017 Mar |
1 |
| 31 |
28063023 | Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. | 2017 Mar |
1 |
| 32 |
28135897 | Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. | 2017 Mar |
1 |
| 33 |
28148395 | Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. | 2017 Apr |
1 |
| 34 |
28445455 | Structural insight into allosteric modulation of protease-activated receptor 2. | 2017 May 4 |
2 |
| 35 |
28881236 | Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations. | 2017 Oct |
2 |
| 36 |
26446588 | Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention. | 2016 May |
3 |
| 37 |
26844674 | Protease-activated receptor 4: from structure to function and back again. | 2016 Oct |
1 |
| 38 |
26876014 | Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50). | 2016 Apr 1 |
1 |
| 39 |
26878340 | Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. | 2016 Aug |
1 |
| 40 |
26966273 | Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking. | 2016 May |
1 |
| 41 |
27054099 | Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis. | 2016 Apr |
2 |
| 42 |
27068977 | Proteinase-activated receptors (PARs) as targets for antiplatelet therapy. | 2016 Apr 15 |
2 |
| 43 |
27261371 | Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. | 2016 Dec |
1 |
| 44 |
27304196 | Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. | 2016 Aug |
1 |
| 45 |
27398626 | Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. | 2016 Nov |
1 |
| 46 |
25467961 | Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. | 2015 May |
1 |
| 47 |
25680760 | Vorapaxar in atherosclerotic disease management. | 2015 May |
1 |
| 48 |
25776457 | Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). | 2015 May 15 |
1 |
| 49 |
25777663 | Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. | 2015 Jul 18 |
1 |
| 50 |
25792124 | Efficacy and safety of vorapaxar as approved for clinical use in the United States. | 2015 Mar 19 |
1 |